The impact of therapeutic drug monitoring in neonatal clinical pharmacology.
Division of Pediatric Clinical Pharmacology, Children's National Health System, Washington, DC, USA; Intensive Care, Erasmus MC-Sophia Children's Hospital, Rotterdam, The Netherlands; Department of Paediatric Pharmacology, University Children's Hospital Basel, Switzerland. Electronic address: jvandena@childrensnational.org.
Johannes N
JN
van den Anker
D000900:Anti-Bacterial Agents / Q000494:pharmacology* / Q000627:therapeutic use; D001424:Bacterial Infections / Q000188:drug therapy; D016903:Drug Monitoring; D006801:Humans; D007231:Infant, Newborn; D007232:Infant, Newborn, Diseases / Q000188:drug therapy; D007363:Intensive Care Units, Neonatal; D008826:Microbial Sensitivity Tests; D058996:Quality Improvement; D016896:Treatment Outcome
D000900:Anti-Bacterial Agents